Novel Fluorine Boron Hybrid Complex as Potential Antiproliferative Drugs on Colorectal Cancer Cell Line

Objective: Colorectal Cancer (CRC) is one of the most common types of cancer in both sexes; it is considered to be the third leading death factor among other types of cancer. This study aimed to examine the cytotoxicity of a new fluorine boron hybrid complex [L(BF2)2] on human colorectal adenocarcinoma cell line (HT-29), based on the potency of the half-metal based complexes to initiate apoptosis. Methods: Based on this data, the impact of it in different concentrations on HT-29 cancerous cells was determined by apoptosis (ELISA, DNA fragmentation laddering, AO/EB staining), cytotoxicity (MTT) and genotoxicity (comet assay). We also calculated the cellular Oxidative Stress Index (OSI) by measuring the Total Antioxidant Status (TAS) and Total Oxidant Status (TOS). Results: Firstly, [L(BF2)2] was examined in view of cytotoxic effect in seven various cell lines (HELA, DU-145, PC3, DLD-1, ECC, PNT1-A and HT-29), and then it was found that the applied complex had a mighty antiproliferative action on HT-29 cells. Thus, the most effective IC50 value turned out to be 26.49 μM in HT-29 cell line. The present study found a tremendous efficacy of [L(BF2)2] on HT-29 cells, especially in terms of damage to cancer cells' DNA, and consequently caused a series of reactions leading to programmed cell death. Conclusion: The results suggest that the [L(BF2)2] as a novel fluorine boron hybrid complex can induce the apoptosis of HT-29 colorectal cancerous cell line and is a possible candidate for future cancer studies.